2010
DOI: 10.1016/j.memsci.2010.01.034
|View full text |Cite
|
Sign up to set email alerts
|

Direct ex vivo expansion of hematopoietic stem cells from umbilical cord blood on membranes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
12
0

Year Published

2011
2011
2021
2021

Publication Types

Select...
4
3
1

Relationship

1
7

Authors

Journals

citations
Cited by 19 publications
(12 citation statements)
references
References 28 publications
0
12
0
Order By: Relevance
“…The human colon carcinoma (HT-29) cell solution or primary colon carcinoma cell solution was filtered through NM filters with r = 11 µm (NM-11) or PGLA-3/SK, PGLA-5/SK, and PGLA-10/SK filters using a batch-type membrane holder (C161, Millipore Corp.) as described previously for blood cell [ 26 , 27 ] or adipose-derived stem cell permeation [ 16 , 28 , 29 , 30 , 31 ]. Figure 1 C shows a schematic representation of a filtration protocol to purify the CICs (CSCs) of colon carcinoma cells from a colon carcinoma cell line (HT-29) and primary colon carcinoma cells.…”
Section: Methodsmentioning
confidence: 99%
“…The human colon carcinoma (HT-29) cell solution or primary colon carcinoma cell solution was filtered through NM filters with r = 11 µm (NM-11) or PGLA-3/SK, PGLA-5/SK, and PGLA-10/SK filters using a batch-type membrane holder (C161, Millipore Corp.) as described previously for blood cell [ 26 , 27 ] or adipose-derived stem cell permeation [ 16 , 28 , 29 , 30 , 31 ]. Figure 1 C shows a schematic representation of a filtration protocol to purify the CICs (CSCs) of colon carcinoma cells from a colon carcinoma cell line (HT-29) and primary colon carcinoma cells.…”
Section: Methodsmentioning
confidence: 99%
“…HSCs are multipotent and have the capability to self-renew and differentiate into all mature blood cells including myeloids such as granulocytes, monocytes, leukocytes, erythrocytes, and megakaryocytes, and lymphoids such as T-lymphocytes and B-lymphocytes ( Figure 2) (Gunsilius, Gastl, & Petzer, 2001;Higuchi et al, 2010). HSCs in UCB are similar to those in BM and peripheral blood in their capacity for differentiation.…”
Section: Hematopoietic Stem Cellsmentioning
confidence: 99%
“…Therefore, a combination of expressed and non-expressed markers are used to identify MSCs. Positive MSC markers include CD29, CD44, CD73 (SH-3, SH-4), CD90 (Thy-1), CD105 (SH-2, Endoglin), and CD166 whereas negative markers include CD11, CD14, CD19, CD31, CD34, CD45, and CD79 (Bieback & Kluter, 2009;Li et al, 2010;Westwood & Clements, 2007).…”
Section: Previous Research Bymentioning
confidence: 99%
“…Based on current clinical experience, the recommended minimum cell dose numbers for successful CB HSC transplantation are 3.5 × 10 7 total nucleated cells (TNC)/kg and 2 × 10 5 CD34 + HSC/kg [17]. Due to the large number of HSCs needed for transplantation (range 1.5 -14.0 × 10 6 /kg) in clinical applications [18,19], largescale ex vivo expansion systems have captured the interest of many researchers [14,[20][21][22][23]. Bioreactor systems such as perfusion chambers [24], stirred bioreactors [25][26][27], rotating wall bioreactors [28], membrane-based bioreactors [29], and packed or fluidized bed reactors [30,31] have been developed and widely tested for ex vivo expansion of HSCs.…”
Section: Introductionmentioning
confidence: 99%